Swiss biotechnology company Lonza Group AG (Lonxa) (SWX: LONN) has agreed with British pharmaceutical company AstraZeneca Plc (STO: AZN) (LON: AZN) to make AZD7442, an experimental combination of two antibodies that may be used to prevent and treat COVID-19, Reuters news agency reported on Friday.
According to Lonxa, AZD7442 is in Phase I clinical studies and AstraZeneca plans to advance the combination into Phase III trials in the coming weeks.
Lonza will manufacture drug substance for AZD7442 at its facilities in the US.
These operations are expected to commence in the first half of 2021.
GSK strengthens pulmonary hypertension pipeline with USD950m acquisition of 35Pharma
Asgard Therapeutics appoints chief medical officer
Mestag Therapeutics to present targeted LTBR agonist MST-0312 at AACR Annual Meeting
hVIVO signs influenza human challenge trial agreement with Traws Pharma
Hoth Therapeutics reports positive HT-VA CRADA data
Kelun-Biotech reports Phase II study results for sac-TMT at 2026 SGO
Genmab reports positive safety data for Rina-S combination in ovarian cancer
GSK reports strong early-stage data for B7-H4 ADC in gynaecological cancers
FDA grants priority review to ifinatamab deruxtecan in small cell lung cancer
Almirall expands supercomputing and AI collaboration with Barcelona Supercomputing Center